Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $0.82
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jul 11, 24 | Maxim Group | upgrade | Hold | Buy |
| Sep 28, 23 | Maxim Group | downgrade | Buy | Hold |
| Mar 31, 23 | Maxim Group | maintain | Buy | Buy |
| Feb 5, 21 | Maxim Group | upgrade | Hold | Buy |
| May 15, 18 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 15, 18 | H.C. Wainwright | maintain | Buy | Buy |
| Aug 17, 17 | Maxim Group | maintain |
Daily · Wilder smoothing
| Buy |
| Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 44.31 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 13.23 | Oscillator | Buy |
| Williams %R (14) | -74.72 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.05 (Hist -0.01) | Oscillator | Strong Sell |
| Average Directional Index (14) | 17.31 (+DI 11.2 / -DI 17.5) | Trend | Neutral |
| EMA 20 | 0.86 | MA | Strong Sell |
| SMA 20 | 0.88 | MA | Strong Sell |
| EMA 50 | 0.92 | MA | Strong Sell |
| SMA 50 | 0.98 | MA | Strong Sell |
| SMA 200 | 0.83 | MA | Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | BCLI | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.9x | -1.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.9x | EPS est. -0.91 | In line |
| Price / Book | -0.8x | -3.5x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -1.1x | -2.1x | Discount |
| Return on equity | 103.7% | — | Top tier |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | -0.12 | -0.29 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -820.35 | Distress |
Discounted cash flow model
Stock news · updated daily
Executive Chairman and Former FDA Associate Commissioner Peter J. Pitts to deliver keynote presentations on establishing an FDA Abraham Accords Office and restructuring NIH research grant models.
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update. "We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm.
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jul 24, 26 | Frenkel Jacob A | director | A-Award | 100,000 | — |
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | -0.29 | -0.35 | Miss -20.7% | — |
| May 15, 2026 | -0.36 | -0.19 | Beat 47.2% | — |
| Mar 31, 2026 | -0.28 | -0.19 | Beat 32.1% | — |
| Nov 14, 2025 | -0.35 | -0.91 | Miss -160.0% | — |
| Aug 14, 2025 | -0.41 | -0.34 | Beat 17.1% | — |
| May 15, 2025 | -0.97 | -0.45 | Beat 53.6% | — |
| Jul 24, 26 |
| Pitts Peter Joe |
| director, officer: Executive Chairman |
| A-Award |
| 900,000 @ $1.00 |
| $900.0K |
| May 25, 26 | Pitts Peter Joe | director | 150,000 @ $0.68 | $102.0K |
| Feb 26, 26 | Lebovits Chaim | officer: President & CEO | A-Award | 1,800,000 | — |
| Feb 26, 26 | Yablonka Uri | director, officer: EVP & Chief Business Officer | A-Award | 150,000 | — |
| Feb 26, 26 | Patlis Alla | officer: See Remarks | A-Award | 100,000 | — |
| Feb 26, 26 | Frenkel Jacob A | director | A-Award | 200,000 | — |
| Feb 26, 26 | Arbel Irit | director | A-Award | 120,000 | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 10-Q | Aug 14, 2026 | 2026-08-14 16:38:30 | View |
| 8-K | Aug 14, 2026 | 2026-08-14 16:16:35 | View |
| 8-K | Jul 30, 2026 | 2026-07-30 16:30:36 | View |
| 4 | Jul 28, 2026 | 2026-07-28 17:01:57 | View |
| 4 | Jul 28, 2026 | 2026-07-28 17:00:07 | View |
| 3 | Jun 3, 2026 | 2026-06-03 17:37:34 | View |
| EFFECT | Jun 2, 2026 | 2026-06-03 00:15:31 | View |
| 4 | May 29, 2026 | 2026-05-29 17:02:36 | View |
| 4 | May 29, 2026 | 2026-05-29 17:02:01 | View |
| 4 | May 29, 2026 | 2026-05-29 17:01:34 | View |
Proxy statement (DEF 14A) disclosures